|
|
2010 Dec: Pharmahungary files patent entitled "stem-cell derived cardiomyocyte-based assay systems". The owners of the patent include members of the ES2HEART consortium sush as Biotalentum Ltd (consortium leading company) and Abiol Ltd. By this patent filing, the number of active patents increased to 3 in the IP portfolio of Pharmahungary Group. Another patent filing is expected in Q1, 2011. 2010 Dec: MMPharma consortium files patent application as a conclusion of a three-year research project. The primary focus of the research was MMP-2 inhibition by small molecules for anti-ischemic and myocardial infarction applications. However, the consortium successfully developed selective inhibitors for not only MMP-2, but MMP-9 and 13 as well, useful targets for treatment of various pathologies. The patent is owned by 3 private Hungarian companies of the MMPharma consortium: Pharmahungary (leader of the consortium), InFarmatik (a drug discovery company), and TargetEx (recombinant protein production and assay development CRO). Since the consortium is actively working to collect additional biological data until the PCT application, further information is available under CDA. For further non-confidential details, see www.MMPharma.com. 2010 Nov: Pharmahungary concluded the development of an upgraded version of its proprietary "infarctsize" system to measure the extent of myocardial infarction in preclinical models. The system consists of a high-thoughput, precision slicing hardware as well as an image analyzer & documentation software designed for the special needs for fast and reproducible measurement and documentation of infarct size. For further details, see www.infarctsize.com. 2010 May: Pharmahungary has got regulatory approval for a Tamiflu pharmacokinetic clinical study (ClinicalTrials.gov Identifier: NCT01130636). The study is sponsored by Pharmahungary and supported by F. Hoffman-La Roche. Patient recruitment starts at the commencement of the official flu endemic season in Hungary. 2010 March 4, Press release: Pharmahungary and Cellmid (Sydney, Australia) sign collaboration and R&D agreements to develop midkine therapies for myocardial infarction. News history, selection: 2009 Q4, 2010 Q1: Pharmahungary launches new services
and products |